Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Nocturia Associated With Nocturnal Polyuria Clinical Trial

Official title: Efficacy and Safety of Nocturin 0.1 mg Tablets in Treatment of Nocturia in Patients With Nocturnal Polyuria, Lower Urinary Tract Symptoms (LUTS) and Benign Prostate Syndrome (BPS).

Status Completed

Clinical Trial Summary

Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lower Urinary Tract Symptoms
• Nocturia
• Nocturia Associated With Nocturnal Polyuria
• Polyuria

• NCT number: NCT00902265
• Study type: Observational
• Source: Ferring Pharmaceuticals
• Status: Completed
• Phase: N/A
• Start date: February 2009
• Completion date: March 2010